TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Immunovia AB ( (SE:IMMNOV) ).
Immunovia AB has increased its number of shares and votes to 672,666,892 as of November 28, 2025, following a rights issue and a directed issue of shares to underwriters. This change, approved by the board and an extraordinary general meeting, reflects the company’s strategic financial maneuvers to support its operations and potentially enhance its market positioning.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing simple tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups. The USA is its largest market, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing. Immunovia’s shares are listed on Nasdaq Stockholm.
Average Trading Volume: 8,406,135
Technical Sentiment Signal: Sell
Current Market Cap: SEK177M
For detailed information about IMMNOV stock, go to TipRanks’ Stock Analysis page.